The estimated Net Worth of Murray A Goldberg is at least 22 百万$ dollars as of 18 May 2020. Murray Goldberg owns over 28,000 units of Ayala Pharmaceuticals stock worth over 18,025$ and over the last 21 years Murray sold AYLA stock worth over 21,986,385$.
Murray has made over 50 trades of the Ayala Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. Most recently Murray exercised 28,000 units of AYLA stock worth 88,200$ on 18 May 2020.
The largest trade Murray's ever made was exercising 151,990 units of Ayala Pharmaceuticals stock on 20 May 2013 worth over 3,041,320$. On average, Murray trades about 14,541 units every 82 days since 2003. As of 18 May 2020 Murray still owns at least 36,050 units of Ayala Pharmaceuticals stock.
You can see the complete history of Murray Goldberg stock trades at the bottom of the page.
Over the last 5 years, insiders at Ayala Pharmaceuticals have traded over 930,844$ worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth 23,628,700$ . The most active insiders traders include Growth Fund Limited Partner...、Murray A Goldberg、Growth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of 102,203$. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth 15,480$.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: